Modulation of gamma secretase to selectively reduce A�42 production is a promising approach to disease modifying therapy for AD.  Using a targeted screening approach, Satori has discovered a novel structural class of gamma secretase modulators (GSMs).  This presentation will focus on the lessons learned during our lead optimization program that have led to the discovery of potent and selective GSMs that exhibit compelling in vitro and in vivo pharmacokinetic profiles.

Discovery and development of a novel class of gamma secretase modulators

243rd National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.